Robin Carhart-Harris, PhD, is a psychologist and neuroscientist and Head of the Centre for Psychedelic Research, Division of Brain Sciences, Faculty of Medicine at Imperial College London.  He coordinated the first clinical study of psilocybin in the UK and the first clinical study of a classic psychedelic drug in the UK for over 40 years.

After being awarded an MA in Psychoanalysis at Brunel University, London, Carhart-Harris completed his PhD in psychopharmacology at the University of Bristol.  In 2009, under the mentorship of Professor David Nutt, he relocated to Imperial College, London to continue his fMRI research with the classic psychedelic psilocybin.  In conjunction with David Nutt, he built up a program of psychedelic research that includes fMR and MEG imaging with psilocybin, fMR imaging with MDMA, and plans for an MRC-sponsored clinical trial to assess the efficacy of psilocybin as a treatment for major depression.

Speaker Disclosures:

Financial: Robin Carhart-Harris has employment relationships with Carhart-Harris Lab and the University of California. He is a consultant with TRYP Therapeutics, the Otsuka group, Entheos Labs, MindState, Osmind, and Journey Collab. Robin Carhart- Harris received a grant from Wellcome Leap. He receives a speaking honorarium from PESI, Inc. All relevant financial relationships with ineligible organizations have been mitigated.

Non-financial: Robin Carhart-Harris is a member of the Association for Psychological Science, the Neuropsychoanalysis Association, and the International Society for Research on Psychedelics.